Skin Appendage Disorders最新文献

{"title":"Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia.","authors":"Sali Alharbi, Azzam Alkhalifah","doi":"10.1159/000550540","DOIUrl":"10.1159/000550540","url":null,"abstract":"<p><strong>Introduction: </strong>Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate remarkable efficacy for weight management, emerging pharmacovigilance data suggest an increased hair loss risk, particularly with newer agents. This study investigated the prevalence, risk factors, and clinical impact of hair shedding in GLP-1 RA users in Saudi Arabia.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted between September 2024 and January 2025 of current and former GLP-1 RA users. Participants with preexisting hair loss were excluded from the study. Hair shedding prevalence, associated factors, and the impact on treatment discontinuation were assessed using validated questionnaires. Multivariate logistic regression was used to identify independent predictors.</p><p><strong>Results: </strong>Among 152 eligible participants (87.5% female, median body mass index 32.1 kg/m²), 70.4% (<i>n</i> = 107) reported hair shedding after GLP-1 RA initiation, which was markedly higher than the 3-7% reported in clinical trials. Tirzepatide users had the highest prevalence (76.7%), followed by semaglutide (64%) and liraglutide (54.5%). Hair shedding was significantly associated with female sex (92.5% vs. 75.6% in males, <i>p</i> = 0.009), greater magnitude of weight loss (82.7% prevalence with ≥15% weight loss vs. 40% with <5%, <i>p</i> = 0.002), and medication discontinuation (63.6% vs. 40% in non-shedders, <i>p</i> = 0.013). Multivariable analysis confirmed independent associations with increasing weight loss (OR 1.79, 95% CI: 1.19-2.76, <i>p</i> = 0.006) and female sex (OR 3.57, 95% CI: 1.20-11.11, <i>p</i> = 0.023). Critically, 39.7% of the affected patients cited hair shedding as their reason for discontinuation, although 37.7% reported resolution after stopping treatment. The median weight loss was 15.9% [IQR 8.69-22.5], with 53.3% achieving ≥15% reduction.</p><p><strong>Conclusion: </strong>Hair shedding affects seven out of ten GLP-1 RA users in real-world settings, representing a ten-fold higher prevalence than that reported in registration trials. This under-recognized phenomenon during GLP-1 RA therapy significantly affects treatment adherence, particularly among women who achieve substantial weight loss. Proactive counseling and nutritional optimization strategies are essential to maintain treatment persistence.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12965749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Update to Ethnoracial Gaps in Global Hidradenitis Suppurativa Clinical Trials.","authors":"Camila R Marquez, Aditya Joshi, Lauren Gawey, Kyla N Price-Jauregui, Mariam Alam, Anna L Cogen, Song Y Park, Olivia R Ware, Jennifer L Hsiao, Vivian Y Shi","doi":"10.1159/000550512","DOIUrl":"10.1159/000550512","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) disproportionately affects ethnoracial minority populations, particularly Black and Hispanic individuals. However, representation in randomized controlled trials remains limited. We aim to assess ethnoracial representation and reporting in HS trials conducted over the past 5 years.</p><p><strong>Methods: </strong>Phase 2 and 3 trials completed between 2019 and 2025 were identified via ClinicalTrials.gov. Trials with results and publications were included. Participant ethnoracial data were extracted, and PubMed supplemented missing data.</p><p><strong>Results: </strong>Among the 17 trials included in analysis, 76.2% (<i>n</i> = 2,652) of participants were white, 13.0% (<i>n</i> = 451) Black/African American, 6.0% (<i>n</i> = 210) Asian, 1.9% (<i>n</i> = 66) more than one race, 1.0% (<i>n</i> = 36) American Indian or Alaska Native, and 0.1% (<i>n</i> = 4) Native Hawaiian or other Pacific Islander. A total of 5.2% (<i>n</i> = 181) were Hispanic/Latino, although only 58.8% (<i>n</i> = 10) of trials reported these data. Of remaining participants, 1.8% (<i>n</i> = 63) were recorded as \"unknown/not reported.\" Geographically, all 17 (100%) trials had site locations in North America, 70.6% (<i>n</i> = 12) of trials had a site location in Europe, 41.2% (<i>n</i> = 7) in Australia, 41.2% (<i>n</i> = 7) in Asia, 11.8% (<i>n</i> = 2) in South America, and 5.9% (<i>n</i> = 1) in Africa.</p><p><strong>Conclusions: </strong>We found improved reporting of race and ethnicity in global HS clinical trials, yet Black and Hispanic/Latino patients remain underrepresented. Additionally, a lack of trials conducted in Africa, Asia, and South America could explain the lack of a global representation in participant demographics. Future trials should conduct stratified analyses to evaluate efficacy across global populations.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147285102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Single-Center Retrospective Analysis of Poroma and Porocarcinoma.","authors":"Nazmiye Selin Salici, Sueda Sanli Arikan, Duygu Yamen, Cem Leblebici, Vefa Asli Erdemir, Ayse Esra Koku Aksu, Mehmet Salih Gurel, Sumeyre Seda Ertekin","doi":"10.1159/000550436","DOIUrl":"10.1159/000550436","url":null,"abstract":"<p><strong>Introduction: </strong>Poroma and porocarcinoma (PC) are rare adnexal tumors with overlapping clinical features, making accurate diagnosis challenging.</p><p><strong>Methods: </strong>We retrospectively analyzed 46 histologically confirmed cases (37 poroma, 9 PC) diagnosed at a single center between 2010 and 2023, comparing demographic, clinical, and histopathological characteristics.</p><p><strong>Results: </strong>Poroma lesions were mainly located on the lower extremities, while PCs predominated on the trunk. Ulceration and bleeding were significantly more frequent in PCs. Among poromas, 24.3% involved the palmoplantar region; all volar lesions were skin-colored to pink-red and had higher clinical diagnostic accuracy than non-volar lesions.</p><p><strong>Conclusion: </strong>Lesion location, morphology, and color are key in evaluating adnexal tumors. Ulceration and bleeding should raise suspicion for PC, emphasizing the need for careful clinical assessment.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12908967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nail Bed Sporotrichosis in a Patient with Psoriasis Arthritis Treated with a TNF Blocker: A Case Report.","authors":"Laura Moya Kazmarek, Elisa Raquel Martins da Costa Marques, Nilton Gioia Di Chiacchio, Jaison Barreto, Alexandre Michalany, Ana Carolina Villas Bôas Weckwerth, Nilton Di Chiacchio","doi":"10.1159/000550351","DOIUrl":"10.1159/000550351","url":null,"abstract":"<p><strong>Introduction: </strong>Sporotrichosis is a granulomatous infection caused by <i>Sporothrix</i> species, typically following traumatic inoculation. Brazil is an endemic area, and zoonotic transmission from cats has become the predominant route of infection. Nail bed involvement is extremely uncommon, likely due to the protective barrier of the nail plate.</p><p><strong>Case presentation: </strong>We report a 51-year-old female, who cared for domestic and stray cats, with cutaneous and arthropathic psoriasis under treatment with methotrexate and adalimumab, who developed a painful, ulcerated lesion on the nail bed and folds of the right third finger 5 days after minor trauma. The lesion was friable, erythematous, and yellowish, associated with onycholysis and nodular lymphangitic spread on the ipsilateral forearm. Histopathology and fungal culture confirmed <i>Sporothrix schenckii</i>. Immunosuppressive therapy was suspended, and oral itraconazole 200 mg twice daily was administered, leading to complete clinical resolution.</p><p><strong>Conclusion: </strong>This case illustrates an uncommon presentation of lymphocutaneous sporotrichosis involving the nail unit in an immunosuppressed patient. The patient showed complete resolution of the condition after treatment with itraconazole.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12975276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147435575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Hyperkeratosis of the First and Fifth Toenails a Neuropathic Manifestation Associated with L5-S1 Nerve Root Compression? A Case Series.","authors":"Ceyda Tetik Aydogdu, Orhan Yilmaz, Miray Kendir, Ozan Aydogdu","doi":"10.1159/000550213","DOIUrl":"10.1159/000550213","url":null,"abstract":"<p><strong>Introduction: </strong>The epidermis and the nervous system share a common embryologic origin from the ectoderm, which explains the coexistence of neurological and cutaneous findings in several conditions. Beyond genodermatoses, peripheral nerve disorders may influence skin appendages, including the nails and hair follicles. Lumbar disc herniation, most commonly occurring at the L4-L5 and L5-S1 levels, can result in chronic compression of nerve roots innervating the dorsal and lateral aspects of the foot. Prolonged neuropathic involvement in this region may lead to subtle but clinically relevant nail changes. This study aimed to evaluate characteristic neuropathy-associated nail alterations in patients with L5-S1 disc herniation and to highlight their potential relevance as indicators of neuropathic involvement.</p><p><strong>Methods: </strong>This observational study included 20 patients with radiologically confirmed L5-S1 disc herniation who presented with localized thickening and discoloration of the nail plate involving the first and fifth toenails. All patients underwent dermatological and neurological examination. Onychomycosis was excluded in all cases through mycological testing.</p><p><strong>Results: </strong>Nail changes were consistently localized to the hallux and fifth toenail. No history of trauma, fungal infection, or primary dermatological disease was identified. The anatomical distribution of the nail findings corresponded to regions innervated by the affected nerve roots.</p><p><strong>Conclusion: </strong>Hyperkeratosis and discoloration of the first and fifth toenails in patients with L5-S1 disc herniation may reflect neuropathic influence on nail morphology. These findings may serve as clinically useful markers for identifying the level of nerve root involvement.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Cetirizine in Androgenetic Alopecia: A Preliminary Study.","authors":"Rachita S Dhurat, Richa Sharma, Chethan Shetty, Nina Mehta, Andy Goren, Torello Lotti","doi":"10.1159/000550279","DOIUrl":"10.1159/000550279","url":null,"abstract":"<p><strong>Introduction: </strong>Prostaglandin D2 (PGD2) is elevated in the bald scalp of men with androgenetic alopecia (AGA) and inhibits hair growth. Cetirizine, an H1-antihistamine, reduces PGD2 production and has anti-inflammatory effects, making it a potential therapeutic candidate.</p><p><strong>Methods: </strong>Ten men aged 18-60 years with Norwood-Hamilton grade III vertex to V AGA applied 1 mL of 1% cetirizine in propylene glycol/butylene glycol daily for 16 weeks. Exclusion criteria included recent use of minoxidil, finasteride, or other antiandrogenic therapies. Hair counts in a 1 cm² tattoo-marked vertex area and blinded photographic assessments were evaluated at baseline and week 16.</p><p><strong>Results: </strong>Nine participants completed the study. Mean hair count increased from 139.6 (SE 13.9) to 163.4 (SE 15.5), a statistically significant change (<i>p</i> = 0.009). Blinded global photographs showed a +2 improvement in 1 patient, +1 in two, and no change in six. Trichoscopic counts improved in all patients. No adverse events occurred.</p><p><strong>Conclusion: </strong>Despite limitations, this report provides additional real-world data supporting cetirizine as a potential therapy in AGA. Larger randomized controlled studies with longer follow-up are needed to establish efficacy, durability, and mechanism of action.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12858242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perception and Use of Complementary and Alternative Medicine among Acne Vulgaris Patients.","authors":"Laitfah Adel Albash, Omnia Abdulmanam Alali, Osama Zuhair Alkhars, Nasser Abdullah Almulhim, Alreem Alaa Albaqshi, Hussain Adel Alsakkak, Fatimah Hussain Almarri, Omar Abdulaziz Alsuwailem, Atheer Ahmad Alalawi, Heba Yousef Alojail, Hussain Sami Alwesaibie","doi":"10.1159/000549533","DOIUrl":"10.1159/000549533","url":null,"abstract":"<p><strong>Introduction: </strong>Acne vulgaris is a chronic skin condition affecting adolescents and adults, often prompting patients to seek complementary and alternative medicine (CAM) due to dissatisfaction with conventional treatments. CAM usage is shaped by cultural beliefs and accessibility, but data in Saudi Arabia remain limited.</p><p><strong>Methodology: </strong>A cross-sectional study was carried out in Al-Ahsa (2024-2025) through an online questionnaire targeting Saudi adults (≥18 years) diagnosed with acne vulgaris.</p><p><strong>Results: </strong>Among 322 respondents, most were aged 18-25 (64.0%) and female (67.1%). Traditional treatments were previously used by 70.5%, mostly topical medications (67.7%), but only 30.3% reported satisfaction. CAM awareness was found in 53.1%, and 44.4% had previously used CAM, primarily nutritional supplements (35.8%). CAM use was significantly associated with age and prior traditional treatment. Side effects were reported by 23.8%, mainly redness (82.5%). Side effects had a higher rate among traditional treatment users. Satisfaction with CAM was significantly linked to acne duration, and history of traditional treatment, though only 19.6% reported satisfaction. In the regression model, older age, adequate acne-related information, and experiencing side effects significantly increased CAM use, while experiencing side effects and family history predicted lower satisfaction with CAM.</p><p><strong>Conclusion: </strong>The study revealed moderate CAM use among acne patients, with nutritional supplements being the most common, with limited satisfaction and some reported side effects. Overall satisfaction with CAM remained low, emphasizing the need for better guidance and integration of safe, evidence-based alternative therapies in acne care.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Onychomatricomas as a Rare Clinical Presentation with BAP1 Mutation: A Case Report.","authors":"Güldehan Atış, Ayşenur Şam Sarı, Gaye Güldiken Doğruel, Pembegül Güneş, Filiz Özen","doi":"10.1159/000550123","DOIUrl":"10.1159/000550123","url":null,"abstract":"<p><strong>Introduction: </strong>Onychomatricoma (OM) is a rare benign fibroepithelial tumor of the nail that originates from the nail matrix and the nail bed. It presents as a solitary lesion and leads to thickening of the nail plate, yellowish longitudinal bands, leuko-xanthonchia, transverse overcurvature, and splinter hemorrhages.</p><p><strong>Case presentation: </strong>We report a 50-year-old woman with complaint of some changes in the shape and color of her thumbnails. On her dermatologic examination, leuko-xanthonchia extending from the distal nail to the lunula, irregularity on the lunula, and erythematous and whitish bands on the lunula were found on her left and right thumbnail. Both lesions were treated surgically. The histopathological evaluation of both lesions was consistent with OM. The <i>BAP1</i> gene was reported as likely pathogenic.</p><p><strong>Conclusion: </strong>OM commonly affects a single nail. The involvement of multiple nails should not be considered a reason to exclude the diagnosis of OM. Multi-nail dystrophies should be considered in case of presence of multiple lesions. In cases with multiple OM, evaluation for a BAP1 mutation should be considered.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hair Products Marketed to Adolescents on Social Media: A Cross-Sectional Study.","authors":"Natalia V Chalupczak, Matilde Iorizzo, Shari R Lipner","doi":"10.1159/000550212","DOIUrl":"10.1159/000550212","url":null,"abstract":"<p><strong>Introduction: </strong>Social media is widely used by adolescents and hair products are frequently promoted on these platforms. However, little is known about marketing strategies or potential dermatologic risks.</p><p><strong>Methods: </strong>We analyzed the first 100 TikTok and 50 Instagram posts using the hashtags \"#teenhaircare,\" \"#tweenhaircare,\" and \"#hairtok\" (10/05/2025-10/15/2025). Eligible posts were English language, ≤2 years old, and promoted hair products or routines intended for adolescents (aged 9-18). Posts were coded for promoter type, marketing strategy, product category, claims, hair type, and ingredients.</p><p><strong>Results: </strong>Influencers comprised 44.7% of creators, and brands accounted for 19.3%. Common marketing strategies included colorful packaging (50.7%) and \"natural/clean\" labeling (27.3%). Key claims included \"shiny hair\" (34%) and \"damage repair\" (26.7%). Most products (82%) contained allergens/irritants such as fragrance, sulfates, silicones, or parabens. Only 2.6% of posts were created by dermatologists and only 6% targeted afro-ethnic hair types.</p><p><strong>Conclusion: </strong>Marketing of adolescent hair products on social media is dominated by influencers with minimal dermatologist oversight. Many promoted products contain allergens or irritants that may contribute to contact dermatitis. Dermatologists should inquire about hair-care practices during adolescent visits and advocate for improved oversight of influencer marketing.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Perspectives regarding Artificial Intelligence-Driven Trichoscopy for Alopecia Evaluation.","authors":"Caitlin A Kearney, Anna L Brinks, Carli N Lawrence, Jerry Shapiro, Mario E Lacouture, Kristen I Lo Sicco","doi":"10.1159/000550043","DOIUrl":"https://doi.org/10.1159/000550043","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia treatment can improve patients' quality of life, but slow hair regrowth makes progress difficult to detect. Trichoscopic measurements (TMs; hair density, hairs/cm²; hair caliber, µm) provide an objective method for monitoring treatment response. Artificial intelligence (AI) enables trichoscopic analysis without hair clippings. This study examines the perspectives of alopecia patients regarding AI-driven trichoscopy.</p><p><strong>Methods: </strong>We conducted an IRB-approved survey study and chart review of 101 patients at the NYU Langone hair clinic undergoing AI-driven trichoscopy. Pre- and post-visit surveys measured self-perceived alopecia severity and quality-of-life impact before and after reviewing TMs with their dermatologist. Opinions regarding AI-driven trichoscopy were assessed via Likert scales. Demographics, medical history, and clinician-assessed severity were extracted from medical charts.</p><p><strong>Results: </strong>Most participants were female (74.3%), white (73.3%), and had nonscarring alopecia (89%). After reviewing TMs, 33.7% of participants reported feeling less bothered by their alopecia, 39.6% perceived reduced severity, and 54.5% noted increased treatment motivation. Among follow-up patients, concordance between patient and physician assessments of interval change in hair loss improved after viewing TMs (<i>p</i> = 0.0075). Patients endorsed enhanced alopecia care and greater confidence in treatment recommendations with the use of AI-driven trichoscopy.</p><p><strong>Conclusion: </strong>Patients with alopecia generally view AI-driven trichoscopy favorably, noting improved quality of care and greater motivation to continue therapy.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12846311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}